Doubt over Sanofi drug in EU may hurt wider MS market
LONDON (Reuters) - Uncertainty over European exclusivity for Sanofi's new multiple sclerosis (MS) pill Aubagio could disrupt the wider market and impact other companies, according to a leading industry analyst.
The French drugmaker won an approval recommendation on Friday for the medicine from the European Medicines Agency, but the regulator refused to give it a "new active substance" (NAS) designation because it is very similar to a much older drug.
Without this designation, Tim Anderson of brokerage Bernstein said generic copies could be launched in Europe in as little as three years - the time required for brief clinical studies of generics and to review applications for approval.
That might not be a disaster for Sanofi, since most of the drug's sales are expected to come from the United States, but Anderson said in a research note it could wreak "havoc" on the rest of the European MS market because of the price disparity that would suddenly exist between generic Aubagio and rivals.
Products that could be hit include injectable MS drugs like Teva's Copaxone and Biogen Idec's Avonex and Tysabri, as well Novartis's MS pill Gilenya. It could also hurt Biogen's new tablet, known as Tecfidera or BG-12, which was recommended for approval in Europe last week.
Sanofi said it was very disappointed by the European regulator's decision on the NAS designation for Aubagio and planned to request a re-examination of the case.
- Islamic State video purports to show beheading of UK hostage David Haines |
- North Korea sentences U.S. citizen Matthew Miller to six years hard labor |
- Scots independence battle reaches fever pitch on streets and screens |
- UK's Cameron resists calls for air strikes despite hostage killing |
- NATO countries have begun arms deliveries to Ukraine: defense minister |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video